{"id":"NCT01470612","sponsor":"Pfizer","briefTitle":"Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis","officialTitle":"A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-01","primaryCompletion":"2020-08-06","completion":"2020-08-06","firstPosted":"2011-11-11","resultsPosted":"2021-09-17","lastUpdate":"2021-09-17"},"enrollment":944,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]}],"arms":[{"label":"CP-690,550 5 mg BID","type":"EXPERIMENTAL"},{"label":"CP-690,550 10 mg BID","type":"EXPERIMENTAL"}],"summary":"This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)","effectByArm":[{"arm":"Tofacitinib 5 mg BID","deltaMin":154,"sd":null},{"arm":"Tofacitinib 10 mg BID","deltaMin":626,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":252,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Colombia","Croatia","Czechia","Denmark","Estonia","France","Germany","Hungary","Israel","Italy","Japan","Latvia","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["38778549","38425446","37560161","37402275","36931693","36526796","36342120","36336750","36242764","36124702","35792493","35648151","35380664","34614208","33884415","33684552","33324993","33127596","33039585","32870265","32816215","32766762","31660640","31599001","31077827","30476584","29850873"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921139&StudyName=Long-Term%20Study%20Of%20CP-690%2C550%20In%20Subjects%20With%20Ulcerative%20Colitis"]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":175},"commonTop":["Nasopharyngitis","Colitis ulcerative","Blood creatine phosphokinase increased","Upper respiratory tract infection","Arthralgia"]}}